Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palucorcel - Janssen Biotech

Drug Profile

Palucorcel - Janssen Biotech

Alternative Names: CNTO-2476

Latest Information Update: 19 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centocor
  • Developer Centocor Ortho Biotech; Janssen Biotech
  • Class Eye disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Age-related macular degeneration
  • No development reported Retinitis pigmentosa

Most Recent Events

  • 05 Jun 2019 Janssen completes the phase II PRELUDE trial in Age-related macular degeneration in USA (Ophthalmic) (NCT02659098)
  • 13 Nov 2017 Janssen Pharmaceutical withdrawn a phase II trial for Age-related macular degeneration (In adults, In the elderly) in Japan, prior to enrolment (Ophthalmic) (NCT02895815) (JapicCTI163414)
  • 31 May 2017 Janssen Pharmaceuticals completes a phase I/II trial in Age-related macular degeneration in USA(Ophthalmic) (NCT01226628)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top